Vol 28, No 6 (2021)
Research Letter
Published online: 2021-10-27
Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases
Abstract
Not available
References
- Abani O, Abbas A, Abbas F, et al. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285): 1637–1645.
- Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021; 384(16): 1491–1502.
- Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 384(1): 20–30.
- Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020; 383(24): 2333–2344.
- Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181(1): 32–40.
- Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021; 384(16): 1503–1516.
- Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181(1): 24–31.
- Veiga VC, Prats JA, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021; 372: n84.
- Akinosoglou K, Velissaris D, Ziazias D, et al. Remdesivir and tocilizumab: Mix or match. J Med Virol. 2021; 93(1): 56–58.
- Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021; 3: CD013881.
